Story
AI Infrastructure Firm Accelevation Sets IPO Terms, Targeting Up to $5.4 Billion Valuation

Summary
AI infrastructure provider Accelevation is targeting a valuation of up to $5.37 billion and aims to raise as much as $720 million in its upcoming U.S. initial public offering, capitalizing on strong investor interest in artificial intelligence.
AI infrastructure provider Accelevation is seeking a valuation of up to $5.37 billion in its U.S. initial public offering, according to a company statement on Tuesday. The move signals another test of investor appetite for technology firms linked to the booming artificial intelligence sector.
Offering Details
The Miamisburg, Ohio-based company, along with certain selling shareholders, plans to offer 30 million shares at a price range of $20 to $24 per share. At the top end of this range, the offering would raise up to $720 million.
Key details of the planned IPO include:
- Proposed Ticker: The company intends to list on the Nasdaq exchange under the symbol “ACCV.”
- Underwriters: A consortium of major banks, including Morgan Stanley, J.P. Morgan, Goldman Sachs, and BofA Securities, are underwriting the deal.
AdMarket Context
Accelevation's public offering joins a wave of companies going public to leverage the market's enthusiasm for AI-related stocks. The performance of recent technology IPOs has been closely watched as a barometer for the health of the broader capital markets.
The inclusion of selling shareholders in the offering means that not all proceeds will go to the company for its own operations or expansion; a portion will go to the existing investors who are cashing out some of their stake.
Read next
More on Stocks
Quest, Labcorp Shares Tumble on Proposed Medicare Reimbursement Cuts
Shares of Quest Diagnostics and Labcorp fell sharply in premarket trading after the Centers for Medicare & Medicaid Services proposed significant cuts to laboratory testing fees, set to begin in 2027.

Roche's Obesity Drug Enicepatide Shows 15.5% Weight Loss in Mid-Stage Diabetes Trial
Swiss drugmaker Roche announced its experimental obesity drug, enicepatide, helped patients with type 2 diabetes achieve an average 15.5% weight loss and significant blood sugar control in a mid-stage study.

DoorDash to Pay $131.5 Million in NYC Settlement Over Worker Pay Issues
Food delivery giant DoorDash has agreed to a $131.5 million settlement with New York City following a probe that found the company underpaid or delayed payments to its delivery workers.

TSX Futures Edge Higher on Mideast Diplomatic Hopes, Eyes on Trump-Xi Summit
Futures for Canada's main stock index saw a modest gain Tuesday morning, influenced by a tech-led rally on Wall Street and tentative hopes for diplomatic progress in the Middle East. Investors are also closely watching an upcoming meeting between U.S. and Chinese leaders.